In this large 🇦🇺 RA cohort, median time on treatment for upadacitinib was lot higher than other JAKi (28mo vs 17mo) Why? Patient selection, or a real difference between JAKi? Would really like more comparative effectiveness data between JAKi #ACR24 OPAL group ABST1370 @RheumNow https://t.co/OU2ayzqIc8

Spicy network SRMA, 123pts w/JAK-TNF-PLBO TNF >> JAK w/respect to malignancy (expected) & better than PLBO (spicy!) JAK > PLBO for heme cancers (makes sense); no significant (but slight trend) toward PLBO > JAK for all cancer The debate continues #ACR24 @RheumNow Abstr#0989 https://t.co/tBnb02gyzF

Brenac et al. Orbital MRI to distinguish GCA AOIN/CRO from non-arteritic. @RheumNow #ACR24 Abstr#1641 https://t.co/qIwaX3qp02 https://t.co/5CIZ0aV98Z

Which RA patients are at increased risk of JAKi adverse events? Does disease activity matter? in the upadacitinib ph3 trials, high disease activity pts had more: serious infections HZ MACE VTE Active RA is a massive contributor to many AEs in JAKi pts #ACR24 ABST1393 @RheumNow https://t.co/DlFf9Sfbja

Koc et al. STAMP trial in PsA. Secukinumab+MTX+GC vs MTX+GC(+SSZ if needed). Both could go to TNF if needed. Secukinumab significantly better at week 12 but no longer at week 24. @RheumNow #ACR24 Abstr#1457 https://t.co/4TGSiUPebV https://t.co/eAANkYIpzy

Harkins @DrTrishHarkins et al. PROs predict relapse in PMR. pVAS, HAQ health status, FACIT-F all positive predictors. Interestingly PHQ-9 negative predictor. @RheumNow #ACR24 Abstr#1238 https://t.co/kj4WgmI0oq https://t.co/xLDzRZvxoA

Gottlieb et al. TYK2i Zasocitinib in PsA. 12 week phase 2 RCT. Skin responses and MDA all favour zasocitinib but maybe not fantastic? PASI75 46%, PASI90 37%, PASI100 26%. MDA in photo. @RheumNow #ACR24 Abstr#1477 https://t.co/iX5iriESV2 https://t.co/RkEmcAZ80x

Zhang @jeffsparks et al. Even more evidence that MTX does not cause ILD, and in fact prevents ILD, in RA, OR 0.48 in meta-analysis. @RheumNow #ACR24 Abstr#1384 https://t.co/YvQnmmvNjF https://t.co/crYUwHahDb

The idea of patient-initiated follow-up for RA is enticing: patient & physician time is already stretched minimize unnecessary visits/improve access but what actually needs to go into the design, to make it safe/workable? A: plenty. 🇨🇦 pilot underway #ACR24 ABST1041 @RheumNow https://t.co/03u4bhnQ0v

STAR trial of GC w/d in RA LDA SEMIRA of GC w/d controlled RA on Toci Very slight disease activity increase, but higher flares No symptomatic adrenal insufficiency, but data of abnormal ACTH stim No good evidence of steroid w/d symptoms Beth Wallace @RheumNow #ACR24 https://t.co/j6UPWlVNIu

Slick poster, but must be careful w/real world data. Big risk of confounding/channeling bias Pts with MACE risk (not always well-characterized by ICD codes) also less likely to receive JAK & therefore less liekly to have subsequent MACE #ACR24 @RheumNow Abstr#1394 https://t.co/lilU0byJ1s

Zhou et al. Phase 2 RCT of XKH004, IL17A/Fi in AxSpA. ASAS40 50.4% vs 25%. Slightly odd dose response variation, but maybe just noise. @RheumNow #ACR24 Abstr#1453 https://t.co/SsTSThFzro https://t.co/C9yK2G4tqB